title: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs.
abstract: The opioid agonist properties of (+/-)-methadone are ascribed almost entirely to the (-)-methadone enantiomer. To extend our knowledge of the pharmacological actions of methadone at ligand-gated ion channels, we investigated the effects of the two enantiomers of methadone and its metabolites R-(+)-2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate (EDDP) and R-(+)-2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline hydrochloride (EMDP), as well as structural analogs of methadone, including (-)-alpha-acetylmethadol hydrochloride (LAAM) and (+)-alpha-propoxyphene, on rat alpha3beta4 neuronal nicotinic acetylcholine receptors (nAChRs) stably expressed in a human embryonic kidney 293 cell line, designated KXalpha3beta4R2. (+/-)-methadone inhibited nicotine-stimulated 86Rb+ efflux from the cells in a concentration-dependent manner with an IC50 value of 1.9 +/- 0.2 microM, indicating that it is a potent nAChR antagonist. The (-)- and (+)-enantiomers of methadone have similar inhibitory potencies on nicotine-stimulated 86Rb+ efflux, with IC50 values of approximately 2 microM. EDDP, the major metabolite of methadone, is even more potent, with an IC50 value of approximately 0.5 microM, making it one of the most potent nicotinic receptor blockers reported. In the presence of (+/-)-methadone, EDDP, or LAAM, the maximum nicotine-stimulated 86Rb+ efflux was markedly decreased, but the EC50 value for nicotine stimulation was altered only slightly, if at all, indicating that these compounds block alpha3beta4 nicotinic receptor function by a noncompetitive mechanism. Consistent with a noncompetitive mechanism, (+/-)-methadone, its metabolites, and structural analogs have very low affinity for nicotinic receptor agonist binding sites in membrane homogenates from KXalpha3beta4R2 cells. We conclude that both enantiomers of methadone and its metabolites as well as LAAM and (+)-alpha-propoxyphene are potent noncompetitive antagonists of alpha3beta4 nAChRs.
authors.affiliation: Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Xiao
authors.forename: R D
authors.initials: RD
authors.lastname: Smith
authors.forename: F S
authors.initials: FS
authors.lastname: Caruso
authors.forename: K J
authors.initials: KJ
authors.lastname: Kellar
mesh_terms: D001667:Binding, Competitive / Q000187:drug effects; D002460:Cell Line; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008691:Methadone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D011869:Radioligand Assay; D011978:Receptors, Nicotinic / Q000187:drug effects*; D012414:Rubidium Radioisotopes; D013237:Stereoisomerism
chemical_list: D009294:Narcotics; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D012414:Rubidium Radioisotopes; C403530:nicotinic receptor alpha3beta4; D009538:Nicotine; D008691:Methadone